1. Home
  2. SNDX vs UTZ Comparison

SNDX vs UTZ Comparison

Compare SNDX & UTZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNDX
  • UTZ
  • Stock Information
  • Founded
  • SNDX 2005
  • UTZ 2018
  • Country
  • SNDX United States
  • UTZ United States
  • Employees
  • SNDX N/A
  • UTZ N/A
  • Industry
  • SNDX Biotechnology: Pharmaceutical Preparations
  • UTZ Packaged Foods
  • Sector
  • SNDX Health Care
  • UTZ Consumer Staples
  • Exchange
  • SNDX Nasdaq
  • UTZ Nasdaq
  • Market Cap
  • SNDX 1.1B
  • UTZ 1.1B
  • IPO Year
  • SNDX 2016
  • UTZ N/A
  • Fundamental
  • Price
  • SNDX $9.92
  • UTZ $13.03
  • Analyst Decision
  • SNDX Strong Buy
  • UTZ Buy
  • Analyst Count
  • SNDX 11
  • UTZ 8
  • Target Price
  • SNDX $34.00
  • UTZ $17.88
  • AVG Volume (30 Days)
  • SNDX 1.7M
  • UTZ 1.1M
  • Earning Date
  • SNDX 08-04-2025
  • UTZ 07-31-2025
  • Dividend Yield
  • SNDX N/A
  • UTZ 1.87%
  • EPS Growth
  • SNDX N/A
  • UTZ 349.84
  • EPS
  • SNDX N/A
  • UTZ 0.21
  • Revenue
  • SNDX $43,722,000.00
  • UTZ $1,425,381,000.00
  • Revenue This Year
  • SNDX $431.08
  • UTZ $2.75
  • Revenue Next Year
  • SNDX $105.38
  • UTZ $2.62
  • P/E Ratio
  • SNDX N/A
  • UTZ $61.09
  • Revenue Growth
  • SNDX N/A
  • UTZ N/A
  • 52 Week Low
  • SNDX $8.58
  • UTZ $11.53
  • 52 Week High
  • SNDX $23.37
  • UTZ $18.89
  • Technical
  • Relative Strength Index (RSI)
  • SNDX 51.66
  • UTZ 38.48
  • Support Level
  • SNDX $9.42
  • UTZ $13.93
  • Resistance Level
  • SNDX $10.75
  • UTZ $14.44
  • Average True Range (ATR)
  • SNDX 0.58
  • UTZ 0.45
  • MACD
  • SNDX 0.08
  • UTZ -0.09
  • Stochastic Oscillator
  • SNDX 51.74
  • UTZ 40.83

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

About UTZ Utz Brands Inc

Utz Brands Inc is a manufacturer of branded salty snacks. It produces a broad offering of salty snacks, including potato chips, tortilla chips, pretzels, cheese snacks, pork skins, pub/party mixes, and other snacks. Its iconic portfolio of authentic, craft, and better-for-you (BFY) brands, which includes Utz, Zapp's, On The Border, Golden Flake, and Boulder Canyon, among others, enjoys household penetration in the United States, where its products can be found in approximately half of U.S. household. The company operates in eight manufacturing facilities with a broad range of capabilities, and its products are distributed nationally to grocery, mass, club, convenience, drug, e-commerce and other retailers through direct shipments, distributors, and approximately 2,500 DSD routes.

Share on Social Networks: